Thymidine kinase cell therapy - MolMed

Drug Profile

Thymidine kinase cell therapy - MolMed

Alternative Names: Herpes simplex virus thymidine kinase (HSV-Tk) donor lymphocytes; HSV-Tk; TBI-0301; TK; TK cell therapy - MolMed; Zalmoxis

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator MolMed
  • Class Cell therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological malignancies; Leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Registered Leukaemia

Most Recent Events

  • 07 Feb 2017 MolMed and TTY Biopharm agree to co-promote and co-develop Thymidine kinase cell therapy in Taiwan, Hong Kong, Singapore, Thailand, Philippines, Vietnam and Malaysia for haematological malignancies
  • 06 Dec 2016 Efficacy data from a pooled analysis of the phase III TK 008 and phase I/II TK 007 trial in Haematological Malignancies presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
  • 01 Dec 2016 MolMed and Megapharm sign a term sheet for supply, registration, sales and distribution of thymidine kinase cell therapy (Zalmoxis) in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top